InspireMD Announces Opening of First Two CGuard™ EPS Centers of Excellence
23 juil. 2018 08h41 HE
|
InspireMD, Inc.
Tel Aviv, Israel, July 23, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), developer of the CGuard™ Embolic Prevention System (EPS) for the prevention of stroke caused by the treatment...
InspireMD’s CGuard EPS Prominently Featured at the 10th International Congress of the Polish Society for Vascular Surgery
18 juin 2018 09h42 HE
|
InspireMD, Inc.
Study results presented from 46 patients treated over two years with zero complicationsPresident of the Polish Society for Vascular Surgery presented clinical cases illustrating the advantages of...
InspireMD’s CGuard™ MicroNet™ EPS Featured in a Live Case Transmission to the 2nd DGA Interventional Congress
11 juin 2018 09h53 HE
|
InspireMD, Inc.
Tel Aviv, Israel, June 11, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Receives Regulatory Approval for both CGuard EPS™ and MGuard Prime™ in Ecuador
16 mai 2018 08h12 HE
|
InspireMD, Inc.
Tel Aviv, Israel, May 16, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today...
InspireMD Reports 132% Increase in CGuard™ EPS Sales for the First Quarter of 2018
07 mai 2018 16h05 HE
|
InspireMD, Inc.
Tel Aviv, Israel, May 07, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces Regulatory Approval and Reimbursement to Commercialize both CGuard EPS™ and MGuard™ Prime Products in Vietnam
30 avr. 2018 07h34 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL, April 30, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Anticipates Fifth Consecutive Quarter of Sequential Double Digit Growth; Projects 132% Increase in CGuard EPS Sales for the First Quarter of 2018; Total Quarterly Company Sales to Exceed $1 Million
03 avr. 2018 10h28 HE
|
InspireMD, Inc.
TEL AVIV, Israel, April 03, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices,...
InspireMD Announces First Patient Treated with CGuard™ EPS in India
05 mars 2018 08h07 HE
|
InspireMD, Inc.
Patient with severe stenosis, calcification and thrombosis successfully treated with CGuard™ EPS TEL AVIV, ISRAEL, March 05, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER:NSPR), a leader...
InspireMD, Inc. Announces Pricing of Public Offering of Common Stock
27 févr. 2018 07h00 HE
|
InspireMD, Inc.
TEL AVIV, ISRAEL , Feb. 27, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE American: NSPR), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular...
InspireMD Announces Exclusive Distribution, Sales and Marketing Agreement for CGuard EPS in South Korea
22 févr. 2018 10h16 HE
|
InspireMD, Inc.
Solvit Medical to fund all regulatory, registration and reimbursement submissions TEL AVIV, ISRAEL, Feb. 22, 2018 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NYSE AMER: NSPR), a leader in...